Lunit Announces 'LunitScope-Based Prediction of Opdivo Efficacy' Results at ESMO

Medical AI company Lunit announced on the 19th that it will present one research abstract utilizing its AI biomarker platform, Lunit Scope, at the 2024 European Society for Medical Oncology (ESMO 2024) held in Barcelona, Spain, from the 13th to the 17th of next month (local time).

Founded in 1975, ESMO is a globally prestigious academic organization with over 30,000 members, including cancer specialists and pharmaceutical and bio industry experts from about 170 countries worldwide. Alongside the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), it is regarded as one of the world's top three cancer societies, providing an in-depth forum every year for the latest cancer research trends and innovative treatment methods.

At this conference, Lunit will present research on "Prediction of treatment response to Opdivo (nivolumab) and chemotherapy combination therapy in patients with advanced gastric cancer through AI-based immune phenotyping classification." Although immune checkpoint inhibitor combination therapy has recently been approved and is used as a first-line treatment for advanced gastric cancer, the variability in treatment response among patients necessitates the discovery of predictive biomarkers for treatment efficacy.

Since 2021, Lunit has participated in ESMO for four consecutive years, presenting various research achievements using Lunit Scope. Through participation in major cancer conferences and sharing research outcomes, the company continues to expand opportunities for collaboration with global pharmaceutical and bio companies while demonstrating the reliability and clinical validity of its AI biomarker technology.

Seobum Seok, CEO of Lunit, stated, "At ESMO 2024, we plan to share further advanced research results of Lunit Scope and strive to apply AI technology in actual clinical settings." He added, "Ultimately, we will faithfully fulfill our role as a leading company contributing to improving the accuracy and efficiency of cancer treatment and enhancing patient survival rates through AI technology."